Another Gold High? Here's the Move Wall Street Is Missing ...

Gold just surged past $3,600, up 45% in a year - but Sean Brodrick says $6,900 could be next. History shows when gold booms, one hidden play has delivered far bigger gains - 21x, 49x, even 1,386x. The same strategy once handed 26,000% profits. And Sean says it's back on the table now.

12 Health Care Stocks Moving In Friday's After-Market Session

Benzinga Insights
September 26, 2025

Gainers

  • Enanta Pharma (NASDAQ: ENTA) stock rose 15.6% to $9.13 during Friday's after-market session. The market value of their outstanding shares is at $165.6 million.
  • OSR Holdings (NASDAQ: OSRH) shares rose 15.42% to $0.67. The company's market cap stands at $12.9 million.
  • Applied DNA Sciences (NASDAQ: APDN) stock moved upwards by 6.76% to $4.42. The company's market cap stands at $1.5 million.
  • Viemed Healthcare (NASDAQ: VMD) stock moved upwards by 6.71% to $7.15. The company's market cap stands at $259.0 million.
  • Advanced Biomed (NASDAQ: ADVB) shares moved upwards by 6.54% to $0.46. The company's market cap stands at $10.1 million.
  • Kindly MD (NASDAQ: NAKA) stock rose 6.08% to $1.22. The market value of their outstanding shares is at $473.9 million.

Losers

  • Applied Therapeutics (NASDAQ: APLT) shares declined by 15.3% to $1.05 during Friday's after-market session. The company's market cap stands at $80.6 million.
  • Zhengye Biotechnology (NASDAQ: ZYBT) stock fell 8.7% to $1.68. The company's market cap stands at $142.1 million.
  • Onconetix (NASDAQ: ONCO) shares decreased by 6.24% to $3.16. The market value of their outstanding shares is at $4.9 million.
  • Indaptus Therapeutics (NASDAQ: INDP) shares decreased by 6.0% to $3.28. The market value of their outstanding shares is at $3.6 million.
  • Evaxion (NASDAQ: EVAX) stock declined by 5.95% to $3.8. The market value of their outstanding shares is at $28.6 million.
  • Skye Bioscience (NASDAQ: SKYE) stock declined by 5.8% to $3.9. The market value of their outstanding shares is at $111.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Continue Reading...

Popular

Nvidia's Value Reaches $4.6 Trillion, Bitcoin Eyes $120,000: What's Moving Markets Thursday?

On the second day of the U.S. government shutdown, Wall Street remains largely subdued, with indexes showing only slight midday declines after touching fresh record highs at the open.

Ondas Holdings Stock Is Hitting New 52-Week Highs Today: Here's Why

Shares of Ondas Holdings Inc. (NASDAQ: ONDS) are soaring Thursday after the autonomous drone infrastructure company said it placed a significant purchase order.

The "Mar-A-Lago Accord" Is Now Underway - Ad

The global order is in chaos. And according to 40-year market veteran Dr. David Eifrig, the biggest controlled demolition of the old monetary order in history could now be here, too. That means if you don't take action today, your wealth could decline by 40%... (Yes, even your cash savings.)

Two Delta jets damaged in 'low-speed collision' on LaGuardia taxiway, injuring 1

Two Delta Air Lines regional jets collided on the taxiway at LaGuardia Airport in New York, injuring a flight attendant, damaging a cockpit and tearing off part of a wing in what the airline described as a “low-speed collision.”

Nvidia Is About to Shock the World: October 23rd - Ad

Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%, is warning everyone to... Mark this date on your calendar: October 23rd! That's when Nvidia could help send shares of this Elon Musk supplier skyrocketing higher.

Donald Trump's Approval Rating Crashes to Record Low — Here's What's Driving the Decline

According to the recent YouGov/Economist poll, President Trump's approval rating has taken a nosedive, reaching its lowest point in his second term.

Cathie Wood Dumps $5.2 Million Worth of This AI Stock, Here's What Ark Bought Instead

Ark Invest decided to sell shares of Tempus AI (TEM), despite positive news of FDA clearance for its diagnostic device. They also made other key trades.

Rare Disease Biotech Offers Access Ahead of Key Milestone - Ad

This late-stage biotech is gearing up for Phase 2 trials with an FDA-designated orphan drug. It's already drawing comparisons to recent billion-dollar exits. Backed by a proven biotech incubator, it's now offering early access to its raise.

Ex-Trump Lawyer Draws Parallels Between Kimmel Suspension And Nazi Regime

Ty Cobb has drawn a comparison between the suspension of comedian Jimmy Kimmel and the tactics employed by the Nazis.

Elon's $25 Trillion Confession - Ad

Elon Musk: "Tesla will become a $25 trillion company." That would make Tesla 8x bigger than Apple today. How is that possible? He admits it's all thanks to this one AI breakthrough that will take AI out of our computer screens and manifest a 250x boom here in the real world.

[Revealed] Trump's Next AI Executive Orders? - Ad

A White House insider with direct ties to Trump's inner circle just revealed what he calls "Manhattan II" - a potential $2.2 trillion AI initiative set to launch as soon as Oct 15. He says this could mirror past U.S. projects that minted fortunes - with small firms soaring 5,000% to 10,000% over two decades. And now he's giving away his #1 stock pick for free before the deadline.

BlackRock Turns Popular Mutual Funds Into Global Equity ETFs

BlackRock turns two top mutual funds into active ETFs, giving investors global equity exposure and strategies to manage volatility.

The Tesla Shock Nobody Sees Coming - Ad

While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.

Biotech With Multiple Orphan Drugs Is Quietly Opening Its Doors - Ad

A promising biotech developing treatments for rare childhood brain diseases is opening a new raise. Its lead drug has fast-track status, orphan designations, is nearing Phase 2 and backed by a Global Integrator.

Anthony Scaramucci Says A Tesla–xAI Merger 'Feels Inevitable' As Shareholders Push For Investment In Grok Parent

Anthony Scaramucci said a Tesla–xAI merger "feels inevitable," amplifying shareholder pressure and investor debate as Musk backs closer ties between the EV maker and his $100 billion AI startup.

Gold Is Being Reintroduced Into the Monetary System - Ad

While the media focuses on political scandals, inflation and coming up with ridiculous acronyms "TACO"... Smart money is tracking a far bigger shift: a gold revaluation is quietly underway. Garrett Goggin, CFA, says this could trigger 100X moves in select miners - and he's identified four with the biggest upside.

Lam Research And JSR Resolve Legal Disputes As They Team Up On AI Era Chips

Lam Research and JSR Corp agreed to collaborate and cross-license, combining their expertise to accelerate semiconductor manufacturing and reduce costs.

New Biotech Offering Targets $426B Rare Disease Market - Ad

The rare disease drug space is growing fast-and so is investor interest. With exclusivity, pricing power and major M&A moves, the rare disease space is getting interesting. This company has the science and the experience.

Crypto Is The Money For AI, Says Economist As Coinbase CEO Teases Stablecoin-Powered Transactions Between Agents

Renowned economist Alex Tabbarok described cryptocurrencies as the “money” for artificial intelligence on Tuesday after Coinbase Global Inc. (NASDAQ:COIN) CEO teased a new feature that enables AI agents to transact using stablecoins.

Another Gold High? Here's the Move Wall Street Is Missing ... - Ad

Gold just surged past $3,600, up 45% in a year - but Sean Brodrick says $6,900 could be next. History shows when gold booms, one hidden play has delivered far bigger gains - 21x, 49x, even 1,386x. The same strategy once handed 26,000% profits. And Sean says it's back on the table now.

Intel, Fedex, Lennar, Brera Holdings And Rivian: Why These 5 Stocks Are On Investors' Radars Today

U.S. stocks closed higher on Thursday, with the Dow Jones Industrial Average up 0.3% at 46,142.42. The S&P 500 advanced 0.5% to 6,631.96, while the Nasdaq climbed nearly 1% to 22,470.73.These are the top stocks that gained the attention of retail traders and investors through the day:

AquaBounty Technologies Stock Explodes Over 98% After Hours: Here's Why

AquaBounty Technologies saw a massive 98.25% surge in after-hours trading to $2.26, following confirmation that it had met NASDAQ's minimum bid price requirement, resolving its earlier delisting risk.

The "Mar-A-Lago Accord" Is Now Underway - Ad

The global order is in chaos. And according to 40-year market veteran Dr. David Eifrig, the biggest controlled demolition of the old monetary order in history could now be here, too. That means if you don't take action today, your wealth could decline by 40%... (Yes, even your cash savings.)

Opendoor Stock Rallies On Expansion And Short Squeeze Hopes

Opendoor stock rallied on Wednesday after it announced an expansion of U.S. operations, but it didn't specify which operations.

Cardlytics Stock Surges 5% After Hours As Citron Research Spotlights Wells Fargo Partnership

Cardlytics Inc. (NASDAQ: CDLX) saw its stock fall 9.85% during regular trading on Thursday. However, the stock rebounded in after-hours trading, climbing 5.04% to $2.50 following positive remarks from analysts.

Nvidia Is About to Shock the World: October 23rd - Ad

Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%, is warning everyone to... Mark this date on your calendar: October 23rd! That's when Nvidia could help send shares of this Elon Musk supplier skyrocketing higher.

Harvard Business School graduate arrested on charges he cheated fellow alums out of over $4 million

NEW YORK (AP) — A Harvard Business School graduate was arrested Thursday on fraud charges alleging he swindled fellow alumni of the prestigious school out of over $4 million in a Ponzi scheme, even assuring one investor they would soon “brag” about their “crazy gains” at the school's reunion.

Rare Disease Biotech Offers Access Ahead of Key Milestone - Ad

This late-stage biotech is gearing up for Phase 2 trials with an FDA-designated orphan drug. It's already drawing comparisons to recent billion-dollar exits. Backed by a proven biotech incubator, it's now offering early access to its raise.

Trending Now

Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.

Copyright trendadvisor.net
Privacy Policy | Terms of Service